57381-59-6

Basic information

• Product Name: Methyl 5-broMo-2-fluorobenzoate
• Synonyms: Methyl 5-broMo-2-fluorobenzoate;Benzoic acid, 5-broMo-2-fluoro-, Methyl ester
• CAS NO: 57381-59-6
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 57381-59-6.mol

Chemical Properties

• Boiling Point: 254.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.577±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 5-broMo-2-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-2-fluorobenzoate(57381-59-6)
• EPA Substance Registry System: Methyl 5-broMo-2-fluorobenzoate(57381-59-6)

Safety Data

• Hazardous Substances Data: 57381-59-6(Hazardous Substances Data)

Usage

Chemical Properties

off-white powder

Upstream product

• 67-56-1 methanol 
• 146328-85-0 5-bromo-2-fluoro-benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 445-29-4 o-fluoro-benzoic acid 

Downstream Products

• 334792-66-4 methyl 6-fluoro-3-(4-hydroxypiperidin-1-yl)benzoate 
• 872459-87-5 methyl-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1031417-94-3 methyl 2-fluoro-5-(2-(trimethylsilyl)ethynyl)benzoate 
• 7364-27-4 5-Bromo-1,2-dihydro-3H-indazol-3-one 
• 394-35-4 methyl 2-fluorobenzoate 
• 1638847-77-4 methyl 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Relevant articles and documents

NOVEL SMALL MOLECULE SHC BLOCKERS FOR TREATING LIVER DISEASE AND METABOLIC DISEASE

The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabo

NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS

The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I) as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.

TRICYCLIC COMPOUND AS CRTH2 INHIBITOR

Provided are a tricyclic compound as shown in formula (I) as a CRTH2 inhibitor, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a solvate thereof, and the use thereof in treating diseases related to CRTH2 receptors.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

Indole derivatives with CRTH2 inhibitor activity

The invention discloses indole derivatives having CRTH2 inhibitor activity and shown as formula (I) in the description or pharmaceutically acceptable salts of the indole derivatives and an applicationof the indole derivatives to treatment of CRTH2 recepto

TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Design, Synthesis, and Evaluation of Novel Auxin Mimic Herbicides

Due to the key roles of auxins as master regulators of plant growth, there is considerable interest in the development of compounds with auxin-like properties for growth management and weed control applications. Herein, we describe the design and multiste

CCR2 MODULATORS

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I) and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.